関連する実験動画
Updated: May 13, 2026

08:31
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
SiO2-薬物複合ナノ粒子の制御可能な薬物放出と同時にキャリア分解
Silu Zhang1, Zhiqin Chu, Chun Yin
1Department of Physics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Journal of the American Chemical Society
|March 19, 2013
まとめ
SiO2製薬ナノ粒子は,制御された薬物放出とキャリア分解を可能にします. このイノベーションは,薬物の投与を容易にし,ナノ粒子断片の効率的な腎臓分泌を促進し,臨床アプリケーションの有望性を示しています.
科学分野:
- バイオマテリアル科学 バイオマテリアル科学
- ナノテクノロジー ナノテクノロジー
- 薬物の配送システムです.
背景:
- シリカ (SiO2) ナノ粒子は生物互換性のある媒介体である.
- 薬物の制御された放出は,効果的な治療法にとって極めて重要です.
- キャリア分解と薬物放出の同時進行は依然として課題です.
研究 の 目的:
- SiO2-薬物複合ナノ粒子を開発し,同時に薬物放出とキャリア分解を行う.
- 薬物の放出とナノ粒子の断片化のメカニズムを調査する.
- この新薬投与システムの臨床翻訳の可能性を評価する.
主な方法:
- SiO2-薬物複合ナノ粒子を放射性薬物濃度グラデントで製造する.
- 拡散によって誘発される薬物放出運動の特徴.
- 薬物分子の脱出によって開始されたナノ粒子分解の観察.
- 発生したキャリア断片のサイズとクリアランスの分析.
主要な成果:
- 薬の同時放出とSiO2キャリアの分解を達成しました.
- 主に拡散によって支配される制御可能な薬剤の放出が実証されています.
- ナノ粒子の中心部から発火した分解を観測した.
- 小さい,腎臓で排泄可能なキャリアフラグメントに断片化が確認されました.
結論:
- SiO2製薬ナノ粒子は,薬の同時放出とキャリア分解を可能にします.
- このシステムは,制御可能な薬物投与と効率的なクリアランスを提供します.
- この技術は,臨床的な翻訳の見通しを持つ診断および治療の応用のための大きな可能性を秘めています.
関連する概念動画
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

